Recipharm To Manufacture Pharmanest's SHACT Lidocaine Delivery Device
By Cyndi Root
Pharmanest announced in a press release that it will be partnering with Recipharm, a contract and development manufacturing organization (CDMO). Pharmanest, an obstetrics and gynecology-focused pharmaceutical company, will partner with Recipharm for the manufacturing of its SHACT medication device. The product is an anesthetic delivery device containing lidocaine for topical administration prior to IUD insertion.
Gunilla Lundmark, CEO at Pharmanest, said, “We look forward to working closely with Recipharm for the commercial manufacture of the product and, indeed, to pooling our respective skills and capabilities to supply the pharmaceutical product to key target markets.”
Recipharm and Pharmanest Agreement
Pharmanest’s focus on pain relief products for women in gynecological care has produced medications and application methods to reduce pain and discomfort. Its SHACT product is a new treatment option for millions of women, for which the company needs reliable manufacturing. Recipharm and Pharmanest have been collaborating and the new long-term agreement is for the launch of SHACT. The two companies plan to offer the product in markets of Pharmanest’s choice, with a launch date to be determined.
SHACT
SHACT is a product that reduces pain during the insertion of an IUD (intrauterine device). The proprietary product contains lidocaine, an anesthetic. The product is applied to the mucous membranes for pain relief. Pharmanest announced in 2013 that SHACT fared well in a Phase II efficacy study. The study of 218 women between 18 and 45 years of age showed that women who received SHACT experienced a 30 percent reduction in pain compared to the placebo group. The SHACT group also experienced less discomfort than the placebo group. A Phase I study showed that SHACT has a rapid action onset as most patients had measurable levels of lidocaine 5 minutes after application. No patients reported adverse events and the most common complaint was nausea.
About Recipharm
Recipharm, with facilities in Sweden, France, the UK, Germany, and Spain, is currently manufacturing over 200 products for pharmaceutical companies. Recently, Recipharm entered a collaboration with CTC Clinical Trial Consultants to provide Phase I support to pharmaceutical companies. Recipharm’s annual report for 2013, released in March 2014, revealed its progress in its core strategies to secure long-term manufacturing contracts and increase intellectual property rights in products and processing technologies.